Ariëns LFM, van der Schaft J, Bakker DS, et al. - Among 138 adult patients with moderate-severe atopic dermatitis (AD) seen in daily practice, researchers determined the influence of 16-week treatment with dupilumab on clinical response and serum biomarkers. They used a prospective multicenter registry named the BioDay registry, to obtain data. They focused on the number of patients achieving EASI-50 (Eczema Area and Severity Index) or EASI-75, as well as patient-reported outcomes measures in order to determine 16-week clinical efficacy of dupilumab. This study included patients suffering from very difficult-to-treat AD, including 84 (61%) who failed treatment on ≥ 2 immunosuppressive drugs. A significant improvement in disease severity and reduction in severity-related serum biomarkers was evident as a result of treatment with dupilumab in patients with very difficult-to-treat AD in a daily practice setting.